Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seattle Genetics Hoping Its Adcetris Trials Can Do Double Duty

This article was originally published in The Pink Sheet Daily

Executive Summary

Story outside: Trials in other indications can suffice as confirmatory trials for accelerated approval in the relapsed/refractory settings, FDA says during advisory committee review
Advertisement

Related Content

Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris
Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris
Oncology Price Scale Tips Higher: Seattle Genetics Adcetris To Cost Over $100K
Oncology Price Scale Tips Higher: Seattle Genetics Adcetris To Cost Over $100K
Adcetris Review Gives ODAC Chance To Apply Principles On Accelerated Approval
Adcetris Review Gives ODAC Chance To Apply Principles On Accelerated Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS072515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel